Abstract:Abstract Lipid peroxidation produces oxidized phospholipids (OxPL) such as oxidized phosphatidylcholine. These compounds react with amino groups of proteins and lipids to form adducts called oxidation specific epitopes (OSEs), which are proinflammatory moieties present on oxidized low density lipoproteins and on apoptotic cells and, unless removed, cause extensive cell damage. Natural antibodies (NAb) produced by B-1 lymphocytes, bind OxPL and prevent their inflammatory activity. E06 is a NAb that recognizes the phosphocholine moiety of OxPL. We previously showed that transgenic expression of a single chain (scFv) form of the antigen-binding domain of E06 IgM (E06-scFv) increases cancellous and cortical bone mass in both male and female mice by increasing bone formation. Age-related bone loss is characterized by a decline in osteoblast number and bone formation, associated with increased oxidative stress and lipid peroxidation. These findings, together with the evidence that serum anti-OxPL IgM titers decrease with age, suggest that increased OxPL formation and decreased anti-OxPL antibodies may contribute to age-related bone loss. Like humans, mice exhibit an age-dependent worsening in glucose tolerance, mainly due to alteration in body composition and increased fat tissue. Chronic low grade inflammation and oxidative stress are associated with development of diabetes mellitus and B-1 lymphocytes have been shown to be protective against obesity associated inflammation, glucose intolerance, and insulin resistance. We tested the hypothesis that overexpression of E06-scFv could attenuate age-related bone loss and glucose intolerance. Serial BMD measurements by DXA of both female and male C57BL/6 E06-scFv transgenic mice (and their WT littermates) up to 22 and 24 months, respectively, showed that E06-scFv attenuated age-related bone loss at the spine and femur in both sexes. As revealed by microCT analysis, this effect was due to the attenuation of the age-associated decline in cancellous bone in both sexes. Additionally, both male and female E06-scFv transgenic mice accumulated less fat mass than WT littermates during aging. Intraperitoneal glucose tolerance test, at 15 months of age, revealed that glucose tolerance was greater in both male and female E06-ScFv mice than in respective WT littermates and did not differ from the glucose tolerance of young mice, indicating that E06-scFv improves glucose metabolism. These data suggest that OxPL impair both age-related bone loss and age-related glucose intolerance. Therefore, targeting OxPL with a neutralizing antibody such as E06, represents a prototypic therapeutic intervention that may simultaneously ameliorate important age-associated diseases.

Glucagon-Like Peptide-2 Ameliorates Age-Associated Bone Loss and Gut Barrier Dysfunction in Senescence-Accelerated Mouse Prone 6 Mice

Glucagon-Like Peptide-2 Improve Intestinal Mucosal Barrier Function in Aged Rats

GLP-2 ameliorates D-galactose induced muscle aging by IGF-1/Pi3k/Akt/FoxO3a signaling pathway in C2C12 cells and mice

Glucagon like peptide 2 has a positive impact on osteoporosis in ovariectomized rats

Inhibiting Glutaminase Exerts Opposite Effects on Ovariectomy-Induced and Age-Related Reductions in Murine Bone Mass

Effect of Aging and Glucagon-like Peptide 2 on Intestinal Microbiota in SD Rats.

Tetrahydroxystilbene Glucoside Delayed Senile Symptoms in Old Mice via Regulation of the AMPK/SIRT1/PGC-1α Signaling Cascade

SUN-346 A Natural Antibody Against Oxidized Phospholipids Attenuates Age-Related Bone Loss and Prevents Age-Related Glucose Intolerance in Mice

Positive effect of peptide-calcium chelates from Grifola frondosa on a mouse model of senile osteoporosis

Functional and multi-omic aging rejuvenation with GLP-1R agonism

Lactobacillus Plantarum 69-2 Combined With Galacto-Oligosaccharides Alleviates D-Galactose-Induced Aging By Regulating The Ampk/Sirt1 Signaling Pathway And Gut Microbiota In Mice

Lacticaseibacillus paracasei LC86 mitigates age-related muscle wasting and cognitive impairment in SAMP8 mice through gut microbiota modulation and the regulation of serum inflammatory factors

Elimination of Senescent Osteocytes by Bone‐Targeting Delivery of Β‐Galactose‐Modified Maytansinoid Prevents Age‐Related Bone Loss

Novel role for alpha-2-macroglobulin (A2M) as a disease modifying protein in senile osteoporosis

Ganoderma Lucidum Polysaccharides Ameliorates D-galactose-induced Aging Salivary Secretion Disorders by Upregulating the Rhythm and Aquaporins.

Effects of GLP-1 Receptor Analogue Liraglutide and DPP-4 Inhibitor Vildagliptin on the Bone Metabolism in ApoE(-/-) Mice

Effects of Osteoglycin (OGN) on treating senile osteoporosis by regulating MSCs

Glucagon‐like Peptide 2 Decreases Osteoclasts by Stimulating Apoptosis Dependent on Nitric Oxide Synthase

GHRH expression plasmid improves osteoporosis and skin damage in aged mice

Local Delivery of Tetramethylpyrazine Eliminates the Senescent Phenotype of Bone Marrow Mesenchymal Stromal Cells and Creates an Anti-Inflammatory and Angiogenic Environment in Aging Mice

Independent Roles of Estrogen Deficiency and Cellular Senescence in the Pathogenesis of Osteoporosis: Evidence in Young Adult Mice and Older Humans